BSEM earnings analysis
What we found in BSEM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BioStem reported Q2 revenue of $7.899 million and EPS of $(0.52), but the provided filing text does not include comparative income-statement, balance-sheet, cash-flow, segment, or margin data. The quarter included approximately $2.5 million of gross equity proceeds from issuing 746,269 shares, supporting liquidity but creating dilution. Management reported effective disclosure controls, no material internal-control changes, and no material changes to previously disclosed risk factors; no quantitative guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q2 revenue and EPS reported
- Q2 revenue was $7.899 million and reported EPS was $(0.52). Prior-period and prior-year comparatives were not included in the provided filing text, so direction and magnitude of change cannot be determined.
- $2.5 million equity financing
- The company raised approximately $2.5 million in gross cash proceeds on May 21, 2026 through the issuance of 746,269 common shares. Net proceeds were intended for working capital and general corporate purposes.
- Meaningful employee option grants
- The company issued 488,233 stock options to 39 employees on April 1, 2026, with total grant-date fair value of $1.660 million, adding to equity-based compensation and potential dilution.
- Controls assessed as effective
- Management stated that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Equity financing and dilution
- The May 21 financing issued 746,269 common shares for approximately $2.5 million, creating shareholder dilution while providing capital for working capital and general corporate purposes.
- Ongoing equity compensation
- The company granted 488,233 options to 39 employees on April 1, 2026, and additional awards included 101,146 options plus 82,456 RSUs to one employee on April 27, 2026. These awards may increase future dilution and compensation expense.
- Quarterly loss and limited visibility
- The company reported Q2 EPS of $(0.52), indicating a quarterly loss; the excerpt does not provide enough income-statement detail to assess whether profitability improved or deteriorated versus the prior quarter or year.
- No disclosed risk-factor update
- The filing states that there were no material changes in risk factors from those previously disclosed in the Form 10 registration statement. Accordingly, no new or updated risk-factor disclosure was identified in the provided excerpt.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.52
What they said about what is next.
The provided filing excerpt contains no quantitative revenue or EPS outlook and does not state whether prior guidance was raised, maintained, lowered, or withdrawn.
The filing reads about the same as the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BSEM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever